Insights
Search Results
Client Highlights
9.21.26
Firm Advises CoVet on Acquisition by IDEXX
On September 16, 2026, IDEXX Laboratories, Inc., a global leader in pet healthcare innovation, announced the acquisition of CoVetAI Inc. (CoVet), a leading and rapidly growing provider of AI-native ambient listening and clinical workflow software for veterinary practices. The financial terms of the transaction were not disclosed. Wilson Sonsini Goodrich & Rosati advised CoVet on the transaction.
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
CoVet helps veterinary teams automatically capture and organize information across the patient care journey, from consultation to treatment planning and client follow-up, reducing documentation burden and saving clinicians’ time. The acquisition expands the value of IDEXX’s software, diagnostics, and AI offerings by making information more accessible, actionable, and connected across the practice. CoVet will be integrated into the IDEXX software ecosystem, which will continue to support other ambient scribe solutions and third-party integrations. CoVet will also continue to integrate with non-IDEXX practice management systems.
The Wilson Sonsini team that advised CoVet on the transaction included:
Client Highlights
9.18.26
Wilson Sonsini Advises Superhuman on Acquisition of Fathom
On September 14, 2026, Superhuman, an AI productivity platform bringing AI to wherever people work, announced its acquisition of Fathom, an AI meeting partner trusted by hundreds of thousands of companies to capture, search, and act on what happens in meetings. Wilson Sonsini Goodrich & Rosati advised Superhuman on the transaction.
Alerts
9.10.26
European Commission Adopts First Article 102 Guidelines on Exclusionary Abuses: Four Key Takeaways for Businesses
On September 3, 2026, the European Commission (EC) adopted its first Guidelines on the application of Article 102 of the Treaty on the Functioning of the European Union (TFEU) to exclusionary abuses of dominance (the Guidelines). The Guidelines provide a comprehensive framework for assessing dominance, exclusionary conduct, and objective justifications under European Union (EU) antitrust rules. The EC intends the Guidelines to increase legal certainty and help companies self-assess their conduct, while also providing a non-binding reference point for European national competition authorities and courts.1
Newsletters
9.09.26
European Antitrust Bimonthly Bulletin – July/August 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Client Highlights
9.03.26
Wilson Sonsini Advises Hugging Face on $12.9 Billion Acquisition by NVIDIA
On September 3, 2026, NVIDIA announced that it has agreed to acquire open-source AI platform Hugging Face for $12.9 billion. Together, NVIDIA and Hugging Face plan to scale Hugging Face’s platform, strengthen its infrastructure, and expand access to AI for developers and institutions worldwide. Wilson Sonsini Goodrich & Rosati advised Hugging Face on the transaction.
Bylined Articles
8.28.26
Law360 Article: “Drug Rulings Clarify Pricing Test and Penalty Reviews”
Wilson Sonsini's Andrew Morrison, Deirdre Carroll, and Jindrich Kloub authored a Law360 article analyzing two UK Court of Appeal rulings that settle the legal test for excessive pricing under competition law. The piece, "Drug Rulings Clarify Pricing Test and Penalty Reviews," examines Pfizer Inc. and another v. Competition (also referred to as Phenytoin II) and Auden Mckenzie and another v. CMA (also referred to as Hydrocortisone II), both involving end-of-life medicines.
Client Highlights
8.20.26
Wilson Sonsini Advises Highspot on Merger with Seismic
On August 18, 2026, Seismic, an AI-powered sales and revenue enablement platform, announced the completion of its merger with Highspot. Following a second request review, the merger obtained U.S. antitrust clearance, which allowed the transaction to close without any action by the Department of Justice Antitrust Division. The combined company will operate under the Seismic name and be led by Seismic Chief Executive Officer Rob Tarkoff. Wilson Sonsini Goodrich & Rosati advised Highspot on the transaction.
Client Highlights
8.17.26
Firm Advises Gravis Robotics on $200 Million Series A
On August 17, 2026, Gravis Robotics, a company retrofitting construction machines with autonomous technology, announced their Series A financing, with SoftBank investing $200 million in the company. The funding is the largest Series A in construction robotics history and will be used to scale autonomous machinery, bringing physical artificial intelligence (AI) directly to construction sites and embedding autonomous systems into heavy machinery fleets. Wilson Sonsini Goodrich & Rosati advised Gravis on the transaction.
Client Highlights
8.06.26
Wilson Sonsini Advises AiDASH on $350 Million Acquisition by Schneider Electric
On July 30, 2026, Schneider Electric, a global energy technology company, announced it has entered a definitive agreement to acquire AiDASH, a cloud-native software company that provides AI-driven vegetation, asset, and climate risk intelligence to utilities and other critical infrastructure operators, in an all-cash transaction with implied enterprise value of $350 million. Wilson Sonsini Goodrich & Rosati is advising AiDASH on the transaction.
Newsletters
7.29.26
European Antitrust Bimonthly Bulletin – May/June 2026
The firm is pleased to distribute the European Antitrust Bimonthly Bulletin, which distills the major antitrust developments in Europe over the past two months into concise and actionable takeaways. Companies operating in, or transacting with, Europe should take note of this quarter's developments in merger enforcement, digital markets regulation, and AI-related antitrust scrutiny.
Client Highlights
7.27.26
Firm Advises Forte Biosciences on $2.2 Billion Acquisition by argenx
On July 27, 2026, argenx, a global immunology innovation company, and Forte Biosciences, a clinical-stage biopharmaceutical company, announced that they have entered into a definitive agreement under which argenx will acquire Forte Biosciences for $77.00 per share in cash, representing a total equity value of approximately $2.2 billion. FB102, Forte Biosciences’ lead program, expands argenx’s portfolio of differentiated immunology medicines, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease and potential to address multiple autoimmune diseases. Wilson Sonsini Goodrich & Rosati advised Forte Biosciences on the transaction.
Alerts
7.14.26
UK Consumer Protection Flies High as CMA Enforces Against Unfair Pricing Practices
Since receiving new powers under the Digital Markets, Competition and Consumers Act 2024 (DMCCA), the UK Competition and Markets Authority (CMA) has pursued an aggressive consumer protection agenda. As previously reported, this began with a series of pricing investigations launched in November 2025, the first of which concluded in April 2026.